THE WOODLANDS, Texas -- Zonagen Inc. said Tuesday that itnearing completion of two strategic alliances with unnamedinternational pharmaceutical companies aimed at taking itscontraceptive vaccine for animals into overseas markets.
The two agreements, one with a Japanese company, areexpected to be signed in August, according to Marty Scudder,Zonagen's chairman. A letter of intent has been signed on oneof the pacts.
The privately held company also announced that its chiefoperating officer, Joseph S. Podolski, was named to theadditional position of president. Podolski succeeds David B.McWilliams, who moved to Houston Biotechnology Inc., butremains a Zonagen director.
Before joining Zonagen in 1989, Podolski was director ofmanufacturing for the Natrasweet division of G.D. Searle & Co.,where he was reponsible for the scale-up and manufacturing ofthe fat substitute Simplesse.
Zonagen last year received a patent for a geneticallyengineered vaccine based on unique proteins to zona pellucida,a shell-like matrix surrounding the eggs of female mammals.The company's vaccine is designed to sterilize and provide non-surgical contraception. Zonagen plans to start field trials of theproduct in 1993 and to start studies later this year on areversible contraceptive in primates.
(c) 1997 American Health Consultants. All rights reserved.